B-cell maturation antigen expression across hematologic cancers: a systematic literature review.
B-Cell Maturation Antigen
/ analysis
Gene Expression Regulation, Neoplastic
Hematologic Neoplasms
/ genetics
Hodgkin Disease
/ genetics
Humans
Leukemia, Lymphocytic, Chronic, B-Cell
/ genetics
Lymphoma, Non-Hodgkin
/ genetics
Multiple Myeloma
/ genetics
Precursor Cell Lymphoblastic Leukemia-Lymphoma
/ genetics
RNA, Messenger
/ genetics
Journal
Blood cancer journal
ISSN: 2044-5385
Titre abrégé: Blood Cancer J
Pays: United States
ID NLM: 101568469
Informations de publication
Date de publication:
30 06 2020
30 06 2020
Historique:
received:
23
12
2019
accepted:
26
05
2020
revised:
21
05
2020
entrez:
2
7
2020
pubmed:
2
7
2020
medline:
11
5
2021
Statut:
epublish
Résumé
B-cell maturation antigen (BCMA) plays a critical role in regulating B-cell proliferation and survival. There is evidence for BCMA expression in various hematologic malignancies, suggesting that BCMA may play an important role as a biomarker or therapeutic target in these diseases. Given advances in understanding the role of BCMA in B-cell development and the promise of BCMA as a therapeutic target, a systematic review is needed to rigorously assess the evidence for BCMA expression and identify areas of consensus and future research. The objective of this review was to summarize the evidence on BCMA protein and mRNA expression across hematologic malignancies. Using a PubMed database search up to 28 August 2019, a systematic literature review of publications reporting BCMA expression in patients with hematologic malignancies was conducted. Data from published congress abstracts presented at the American Society of Clinical Oncology and the American Society of Hematology were also searched. Studies that assessed BCMA expression (protein or mRNA) in patients of any age with hematologic malignancies were included. A total of 21 studies met inclusion criteria and were included in the review. BCMA was expressed in several hematologic malignancies, including multiple myeloma (MM), chronic lymphocytic leukemia, acute B-lymphoblastic leukemia, non-Hodgkin lymphoma (NHL), and Hodgkin lymphoma. BCMA was expressed at uniformly high levels across all 13 MM studies and at low to moderate levels in acute myeloid leukemia and acute lymphoblastic leukemia. These results suggest that BCMA is a relevant target in MM as well as in a subset of B-cell leukemia. BCMA expression in Hodgkin lymphoma and NHL varied across studies, and further research is needed to determine the utility of BCMA as an antibody target and biomarker in these diseases. Differences in sample type, timing of sample collection, and laboratory technique used may have affected the reporting of BCMA levels.
Identifiants
pubmed: 32606424
doi: 10.1038/s41408-020-0337-y
pii: 10.1038/s41408-020-0337-y
pmc: PMC7327051
doi:
Substances chimiques
B-Cell Maturation Antigen
0
RNA, Messenger
0
TNFRSF17 protein, human
0
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
73Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Références
Tai, Y. T. & Anderson, K. C. Targeting B-cell maturation antigen in multiple myeloma. Immunotherapy 7, 1187–1199 (2015).
pubmed: 26370838
pmcid: 4976846
O’Connor, B. P. et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J. Exp. Med. 199, 91–98 (2004).
pubmed: 14707116
pmcid: 1887725
Laurent, S. A. et al. γ-secretase directly sheds the survival receptor BCMA from plasma cells. Nat. Commun. 6, 7333 (2015).
pubmed: 26065893
pmcid: 4490565
Cho, S. F., Anderson, K. C. & Tai, Y. T. Targeting B cell maturation antigen (BCMA) in multiple myeloma: potential uses of BCMA-based immunotherapy. Front. Immunol. 9, 1821 (2018).
pubmed: 30147690
pmcid: 6095983
Topp, M. S. et al. Anti-B-cell maturation antigen BiTE molecule AMG 420 induces response in multiple myeloma. J. Clin. Oncol. 38, 775–783 (2020).
pubmed: 31895611
Shah, N. et al. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia 34, 985–1005 (2020).
pubmed: 32055000
pmcid: 7214244
Cohen, A. D. et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J. Clin. Invest. 129, 2210–2221 (2019).
pubmed: 30896447
pmcid: 6546468
Brudno, J. N. et al. T cells genetically modified to express an anti–B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma. J. Clin. Oncol. 36, 2267–2280 (2018).
pubmed: 29812997
pmcid: 6067798
Trudel, S. et al. Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. Lancet Oncol. 19, 1641–1653 (2018). Blood 2017;130:741.
pubmed: 30442502
pmcid: 6328058
Khattar, P. et al. B-cell maturation antigen is exclusively expressed in a wide range of B-cell and plasma cell neoplasm and in a potential therapeutic target for Bcma directed therapies. Blood 130, 2755 (2017).
Maia, S. et al. Aberrant expression of functional BAFF-system receptors by malignant B-cell precursors impacts leukemia cell survival. PLoS ONE 6, e20787 (2011).
pubmed: 21687682
pmcid: 3110793
Liberati, A. et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern. Med. 151, W65–W94 (2009).
pubmed: 19622512
Seckinger, A. et al. Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment. Cancer Cell 31, 396–410 (2017).
pubmed: 28262554
Lee, L. et al. Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma. Br. J. Haematol. 174, 911–922 (2016).
pubmed: 27313079
Quinn, J. et al. APRIL promotes cell-cycle progression in primary multiple myeloma cells: influence of D-type cyclin group and translocation status. Blood 117, 890–901 (2011).
pubmed: 20709908
Tai, Y.-T. et al. Novel anti–B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood 123, 3128–3138 (2014).
pubmed: 24569262
pmcid: 4023420
Carpenter, R. O. et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin. Cancer Res. 19, 2048–2060 (2013).
pubmed: 23344265
pmcid: 3630268
Kinneer, K. et al. Preclinical assessment of an antibody-PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells. Leukemia 33, 766–771 (2019).
pubmed: 30315237
Pilarski, L. M. & Belch, A. R. Clonotypic myeloma cells able to xenograft myeloma to nonobese diabetic severe combined immunodeficient mice copurify with CD34(+) hematopoietic progenitors. Clin. Cancer Res. 8, 3198–3204 (2002).
pubmed: 12374689
Reghunathan, R. et al. Clonogenic multiple myeloma cells have shared stemness signature associated with patient survival. Oncotarget 4, 1230–1240 (2013).
pubmed: 23985559
pmcid: 3787153
Friedman, K. M. et al. Effective targeting of multiple B-cell maturation antigen-expressing hematological malignances by anti-B-cell maturation antigen chimeric antigen receptor T cells. Hum. Gene Ther. 29, 585–601 (2018).
pubmed: 29641319
pmcid: 5930946
Nilsson, K. et al. Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from IgE myeloma patient. Clin. Exp. Immunol. 7, 447–489. (1970).
Matsuoka, Y. et al. Production of free light chains of immunoglobulin by a hematopoietic cell line derived from a patient with multiple myeloma. Proc. Soc. Exp. Biol. Med. 125, 1246–1250 (1967).
pubmed: 6042436
Bluhm, J. et al. CAR T cells with enhanced sensitivity to B cell maturation antigen for the targeting of B cell non-Hodgkin’s lymphoma and multiple myeloma. Mol. Ther. 26, 1906–1920 (2018).
pubmed: 30078440
pmcid: 6094395
Sanchez, E. et al. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br. J. Haematol. 158, 727–738 (2012).
pubmed: 22804669
Sanchez, E. et al. Soluble B-cell maturation antigen mediates tumor-induced immune deficiency in multiple myeloma. Clin. Cancer Res. 22, 3383–3397 (2016).
pubmed: 26960399
Ghermezi, M. et al. Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients. Haematologica 102, 785–795 (2017).
pubmed: 28034989
pmcid: 5395119
Bellucci, R. et al. Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor. Blood 105, 3945–3950 (2005).
pubmed: 15692072
pmcid: 1895080
Bolkun, L. et al. Involvement of BAFF and APRIL in resistance to apoptosis of acute myeloid leukemia. J. Cancer 7, 1979–1983 (2016).
pubmed: 27877213
pmcid: 5118661
Sun, B. et al. Raised expression of APRIL in Chinese children with acute lymphoblastic leukemia and its clinical implications. J. Pediatr. Hematol. Oncol. 36, 276–280 (2014).
pubmed: 23887020
Novak, A. J. et al. Expression of BLyS and ist receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. Blood 104, 2247–2253 (2004).
pubmed: 15251985
Elsawa, S. F. et al. B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenström macroglobulinemia. Blood 107, 2882–2888 (2006).
pubmed: 16304043
pmcid: 1895377
Ferrer, G. et al. B cell activation through CD40 and IL4R ligation modulates the response of chronic lymphocytic leukaemia cells to BAFF and APRIL. Br. J. Haematol. 164, 570–578 (2014).
pubmed: 24245956
Cols, M. et al. Stromal endothelial cells establish a bidirectional crosstalk with chronic lymphocytic leukemia cells through the TNF-related factors BAFF, APRIL and CD40L. J. Immunol. 188, 6071–6083 (2012).
pubmed: 22593611
pmcid: 3370079
Chiu, A. et al. Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL. Blood 109, 729–739 (2007).
pubmed: 16960154
pmcid: 1785096
Salem, D. A. et al. Quantification of B-cell maturation antigen, a target for novel chimeric antigen receptor T-cell therapy in myeloma. Leuk. Res. 71, 106–111 (2018).
pubmed: 30053652
Pekmezci, M. et al. The effect of cold ischemia time and/or formalin fixation on estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2 results in breast carcinoma. Patholog. Res. Int. 2012, 947041 (2012).
pubmed: 22482085
pmcid: 3317053
Engel, K. B. & Moore, H. M. Effects of preanalytical variables on the detection of proteins by immunohistochemistry in formalin-fixed, paraffin-embedded tissue. Arch. Pathol. Lab. Med. 135, 537–543 (2011).
pubmed: 21526952
Edfors, F. et al. Gene-specific correlation of RNA and protein levels in human cells and tissues. Mol. Syst. Biol. 12, 883 (2016).
pubmed: 27951527
pmcid: 5081484
Abreau, De. Sousa R. et al. Global signatures of protein and mRNA expression levels. Global signatures of protein and mRNA expression levels. Mol. Biosyst. 5, 1512–1526 (2009).
Pont, M. J. et al. γ-secretase inhibition increases efficacy of BCMA-specific Chimeric Antigen Receptor T Cells in multiple myeloma. Blood 134, 1585–1597 (2019).
pubmed: 31558469
Cowan, A. J. et al. Efficacy and safety of fully human Bcma CAR T cells in combination with a gamma secretase inhibitor to increase Bcma surface expression in patients with relapsed or refractory multiple myeloma. Blood 143(Supplement_1), 204 (2019).
Gazdar, A. F. et al. Establishment and characterization of a human plasma cell myeloma culture having a rearranged cellular myc proto-oncogene. Blood 67, 1542–1549 (1986).
pubmed: 2423157
Greenstein, S. et al. Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells. Exp. Hematol. 31, 271–282 (2003).
pubmed: 12691914
Togawa, A. et al. Establishment and characterization of a human myeloma cell line (KMM-1). Int. J. Cancer 29, 495–500 (1982).
pubmed: 7095894